Botanix Secures ~AU$45 Million to Fund API Supply and Accelerate Sofdra Growth
Botanix Pharmaceuticals Limited (ASX: BOT) has received firm commitments to raise approximately AU$40 million via a two-tranche placement priced at AU$0.06 per share, alongside plans to launch a security purchase plan (SPP) targeting up to AU$5 million, bringing the total capital raise to around AU$45 million before costs. Directors and the Chief Executive Officer have collectively committed approximately AU$500,000, subject to shareholder approval.
Proceeds will be used to fund active pharmaceutical ingredient (API) purchases, manufacturing inputs, onboarding of alternative API suppliers, marketing initiatives, operating costs, and working capital. A key objective is to diversify supply chains and reduce cost of goods sold by an estimated 25% to 40% over time. The capital raise strengthens Botanix’s balance sheet as it continues scaling Sofdra® prescriptions, expanding its sales force, and evaluating strategic growth opportunities, including potential mergers and acquisitions.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Botanix Secures ~AU$45 Million to Fund API Supply and Accelerate Sofdra Growth
Botanix Pharmaceuticals Limited (ASX: BOT) has received firm commitments to raise approximately AU$40 million via a two-tranche placement priced at AU$0.06 per share, alongside plans to launch a security purchase plan (SPP) targeting up to AU$5 million, bringing the total capital raise to around AU$45 million before costs. Directors and the Chief Executive Officer have collectively committed approximately AU$500,000, subject to shareholder approval.
Proceeds will be used to fund active pharmaceutical ingredient (API) purchases, manufacturing inputs, onboarding of alternative API suppliers, marketing initiatives, operating costs, and working capital. A key objective is to diversify supply chains and reduce cost of goods sold by an estimated 25% to 40% over time. The capital raise strengthens Botanix’s balance sheet as it continues scaling Sofdra® prescriptions, expanding its sales force, and evaluating strategic growth opportunities, including potential mergers and acquisitions.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au